<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309838</url>
  </required_header>
  <id_info>
    <org_study_id>LPS-II</org_study_id>
    <nct_id>NCT04309838</nct_id>
  </id_info>
  <brief_title>Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension</brief_title>
  <acronym>LPS-II</acronym>
  <official_title>LENUS Pro® Study (LPS-II) - Observation Study With Implantable Medication Pump for Intravenous REMODULIN® (Treprostinil) Therapy in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OMT GmbH &amp; Co. KG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a non-interventional, multicenter, prospective single-arm study to
      observe the therapy with REMODULIN (Treprostinil) applicated by an implantable pump in
      patients with pulmonary arterial hypertension (PAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients that suffer from progressing PAH are medicated with intravenous prostanoids since
      the 80's of the last century. Nowadays, specific treatment of PAH can be realized by the huge
      number of substances that are currently available. Still, the time point of starting an
      intravenous medication is not defined yet. By evaluation of data concerning risk strata of
      PAH patients, this issue may be enlightened properly.

      Previously collected data concerning risk-adapted therapy in PAH-patient have shown that the
      mortality is little in the &quot;low-risk-status&quot; patients, only. Thus, all efforts must be
      undertaken to define the patients in this functional class. For most patients this means a
      combined therapy of available substances according to well defined procedures. Patients whose
      status remain as &quot;intermediate-risk-status&quot; after receiving a dual therapy over 3-6 months
      shall undergo a subsequent triple therapy including Selexipag. However, this therapy may not
      lead to an improvement of the risk-status or even worsened. In these cases, a subcutaneous or
      intravenous therapy with prostanoids is indicated.

      Currently, there are no data available for those patients treated with at least three months
      with Selexipag as part of a triple therapy that undergo a subsequent intravenous therapy with
      Treprostinil if there is no change in their risk-status. In the planned study LPS-II,
      patients are specifically selected on being treated in a dual therapy and having a stagnating
      intermediate-risk status. These patients receive an implantation of the medical pump LENUS
      pro, that enables a permanent infusion of Treprostinil.

      The aim of this study is to examine, whether patients can reach an improvement in their
      intermediate-risk-status after six months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of clinical stability criteria</measure>
    <time_frame>Baseline and after 6 months intravenous therapy with Treprostinil</time_frame>
    <description>to achieve &quot;low-risk-status&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline and after 6 months intravenous therapy with Treprostinil</time_frame>
    <description>Assessment of Quality of Life by EQ-5D-5F questionnaire (patient reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restrictions caused by the implant</measure>
    <time_frame>immediately after implantation until 6 months intravenous therapy with Treprostinil</time_frame>
    <description>Assessment of restrictions that may cause by the implant: mobility, pain, rubor, swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polysomnography</measure>
    <time_frame>Baseline and after 6 months intravenous therapy with Treprostinil</time_frame>
    <description>Record of hypnogram: duration of sleep, respiratory analysis, quantity and severity of apnea and hypopnea, snoring, oxygen saturation, heart rate, Continuous Positive Airway Pressure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events associated with the implant</measure>
    <time_frame>at any visit</time_frame>
    <description>Record of all security related adverse events related to implantation of the pump: infections (local, systemic), seroma/hematoma, dysfunction of the pump, other complications associated with the catheter</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>PAH</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Treprostinil via implanted pump</intervention_name>
    <description>Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with PAH (Pulmonary arterial hypertension) who need to undergo treatment with
        Treprostinil, administered by an intravenous pump system (LENUS pro)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of pulmonary arterial hypertension (WHO group I) accordingly to
             international guidelines

          -  intermediate or high risk-profile of PAH after at least three months treatment with
             vasoactive substances including Selexipag

          -  indication of intravenous therapy with Treprostinil

          -  informed consent given for implantation of the medical pump LENUS pro

          -  informed consent given for participation in the LPS-II study

        Exclusion Criteria:

          -  contraindications according to package information leaflet (LENUS pro) and/or summary
             of product characteristics (Treprostinil)

          -  Patient is diagnosed with PAH with an etiology different from that of the inclusion
             criteria

          -  chronic kidney insufficiency (estimated GFR &lt; 30)

          -  hepatic insufficiency: CHILD C (known information from patients medical records)

          -  intake of substances with potential for infections: intravenous drug abuse,
             prednisolone, azathioprine, cyclophosphamide

          -  suffering from diseases with potential for infections: immunodeficiency syndrome,
             diabetes mellitus, diabetic gangrene

          -  pregnant or breastfeeding women

          -  women of childbearing potential who are not on a reliable and safe form of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ralf Ewert, Prof. MD</last_name>
    <phone>+49 3834 86</phone>
    <phone_ext>80596</phone_ext>
    <email>ralf.ewert@med.uni-greifswald.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian F Opitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Henning Gall, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Manuel Richter, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ralf Ewert, Prof. MD</last_name>
      <phone>+49 3834 86</phone>
      <phone_ext>80598</phone_ext>
      <email>ralf.ewert@med.uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans FE Klose, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen Olsson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marius M Hoeper, Prof. MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ekkehard Grünig, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Rosenkranz, Prof. MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Felix Gerhardt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Lange, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Treprostinil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

